This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
Key expert takeaways on the IRA, European court expansion, and patent delisting for life sciences leaders.
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
Investing in the prevention and treatment of non-communicable diseases (NCDs) can strengthen health systems, protect economic productivity, and improve...
